The cost‐effectiveness of dapagliflozin compared to DPP‐4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands

N. van der Linden, S. van Olst, S. Nekeman, C.A. Uyl-de Groot

Research output: Contribution to journal › Article › Academic › peer-review

6 Citations (Scopus)
108 Downloads (Pure)

Fingerprint

Dive into the research topics of 'The cost‐effectiveness of dapagliflozin compared to DPP‐4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry